Literature DB >> 24953075

The role of screening tools in diagnosing neuropathic pain.

Matthew R Mulvey1, Michael I Bennett, Iris Liwowsky, Rainer Freynhagen.   

Abstract

Neuropathic pain affects 6-8% of the general adult population. It is reported by 27% of chronic pain patients and 40% of cancer patients, yet there is no standardized diagnostic test for neuropathic pain. A number of screening tools have been developed based on verbal pain descriptors, with or without limited clinical examination, to identify individuals with neuropathic pain. Over the past decade these neuropathic pain screening tools have been validated in a wide range of pain populations, as well as translated into many languages, to discriminate between neuropathic and non-neuropathic pain. We describe here the five most commonly used neuropathic pain screening tools and discuss current assessment guidelines, the use of screening tools in novel clinical contexts and their potential use in personalized therapy.

Entities:  

Mesh:

Year:  2014        PMID: 24953075     DOI: 10.2217/pmt.14.8

Source DB:  PubMed          Journal:  Pain Manag        ISSN: 1758-1869


  11 in total

1.  Neuropathic Pain Screening: Construct Validity in Patients With Sickle Cell Disease.

Authors:  Keesha Powell-Roach; Yingwei Yao; Miriam O Ezenwa; Judith M Schlaeger; Marie L Suarez; Robert E Molokie; Zaijie Jim Wang; Diana J Wilkie
Journal:  West J Nurs Res       Date:  2019-03-22       Impact factor: 1.967

2.  A PROMIS Measure of Neuropathic Pain Quality.

Authors:  Robert L Askew; Karon F Cook; Francis J Keefe; Cindy J Nowinski; David Cella; Dennis A Revicki; Esi M Morgan DeWitt; Kaleb Michaud; Dace L Trence; Dagmar Amtmann
Journal:  Value Health       Date:  2016-04-06       Impact factor: 5.725

3.  The management of chronic osteoarticular pain in the outpatient setting: results of an ASON audit.

Authors:  Massimo Mammucari; Sergio Gigliotti; Angelo Pucino; Maria Capezza; Giuseppe Santé
Journal:  Joints       Date:  2016-01-28

4.  Systemic Injection of Thalidomide Prevent and Attenuate Neuropathic Pain and Alleviate Neuroinflammatory Response in the Spinal Dorsal Horn.

Authors:  Hao Xu; Sha-Jie Dang; Yuan-Yuan Cui; Zhen-Yu Wu; Jun-Feng Zhang; Xiao-Peng Mei; Yu-Peng Feng; Yun-Qing Li
Journal:  J Pain Res       Date:  2019-11-29       Impact factor: 3.133

5.  The Modified painDETECT Questionnaire for Patients with Hip or Knee Osteoarthritis: Translation into Dutch, Cross-Cultural Adaptation and Reliability Assessment.

Authors:  Wietske Rienstra; Tim Blikman; Frans B Mensink; Jos J A M van Raay; Baukje Dijkstra; Sjoerd K Bulstra; Martin Stevens; Inge van den Akker-Scheek
Journal:  PLoS One       Date:  2015-12-31       Impact factor: 3.240

6.  Characterizing individual painDETECT symptoms by average pain severity.

Authors:  Alesia Sadosky; Vijaya Koduru; E Jay Bienen; Joseph C Cappelleri
Journal:  Clinicoecon Outcomes Res       Date:  2016-07-26

7.  Dehydrocrenatidine Inhibits Voltage-Gated Sodium Channels and Ameliorates Mechanic Allodia in a Rat Model of Neuropathic Pain.

Authors:  Fang Zhao; Qinglian Tang; Jian Xu; Shuangyan Wang; Shaoheng Li; Xiaohan Zou; Zhengyu Cao
Journal:  Toxins (Basel)       Date:  2019-04-18       Impact factor: 4.546

8.  Adaptation, validity and reliability of the modified painDETECT questionnaire for patients with subacromial pain syndrome.

Authors:  Barbara C Boer; Jolanda Boetje; Martin Stevens; Inge van den Akker-Scheek; Jos J A M van Raay
Journal:  PLoS One       Date:  2019-02-06       Impact factor: 3.240

9.  Genitofemoral neuralgia: adding to the burden of chronic vulvar pain.

Authors:  Hans Verstraelen; Eline De Zutter; Martine De Muynck
Journal:  J Pain Res       Date:  2015-11-30       Impact factor: 3.133

10.  Neuropathic-like symptoms and the association with joint-specific function and quality of life in patients with hip and knee osteoarthritis.

Authors:  Tim Blikman; Wietske Rienstra; Jos J A M van Raay; Baukje Dijkstra; Sjoerd K Bulstra; Martin Stevens; Inge van den Akker-Scheek
Journal:  PLoS One       Date:  2018-06-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.